Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Etavopivat - Forma therapeutics

Next Previous
X
Search
Drug Profile

Etavopivat - Forma therapeutics

Alternative Names: FT-4202; NN 7535; NN-7536; NN7535 – Etavopivat in SCD; NN7535 – Etavopivat in Sickle cell disease; NN7536 – Etavopivat in Beta thalassemia

Latest Information Update: 04 Sep 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator FORMA Therapeutics
  • Class Antianaemics; Small molecules
  • Mechanism of Action Pyruvate kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sickle cell anaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Sickle cell anaemia
  • Phase II Myelodysplastic syndromes; Thalassaemia

Most Recent Events

  • 04 Sep 2024 Phase-I clinical trials in Sickle cell anaemia (In volunteers) in China (PO) (NCT06581627)
  • 26 Aug 2024 Phase-I clinical trials in Thalassaemia (In volunteers) in China (PO) (NCT06581627)
  • 28 May 2024 Novo Nordisk initiates a pharmacokinetic phase I trial for sickle cell anemia and thalassemia (In volunteers) in the US (NCT06433661)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top